PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportspolycythemia vera
MeSH D011087 - polycythemia vera
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D019046:Bone marrow neoplasms
0 Companies
0 Drugs
Success rate
D009196:Myeloproliferative disorders
2 Companies
2 Drugs
$
Success rate
D011087: 
Polycythemia vera
39 Companies
8 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaAnagrelide Anagrelide  2005-04-18   
MylanAnagrelide Anagrelide Mylan  2018-02-15   
Busulfan Busulfan  2018-07-13   
NovartisRuxolitinib Jakavi  2012-08-23 $1,702 M Q2/21-Q2/24 
Merck & CoInterferon alfa-2b Intron A  1986-06-04   
Interferon alfa-2b IntronA  2000-03-09   
Interferon alfa-2b Viraferon  2000-03-09   
TakedaAnagrelide Agrylin  1997-03-14   
Anagrelide Xagrid  2004-11-15   
Barr PharmaceuticalsAnagrelide Anagrelide  2005-04-18   
Hydroxyurea Hydroxyurea  1998-07-30   
Rising PharmaceuticalsAnagrelide Anagrelide  2006-06-27   
ApotexBusulfan Busulfan  2019-05-07   
Torrent PharmaceuticalsAnagrelide Anagrelide  2017-06-30   
HospiraBusulfan Busulfan  2018-07-31   
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
70%
21/30
Phase 2
15%
9/62
Phase 3
74%
14/19
Approved: 10Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Mylan
Anagrelide
Novartis
Ruxolitinib,
Sabatolimab,
Spartalizumab,
Ademetionine,
Sodium lactate,
Albinterferon alfa-2b,
Aspartame,
Bevifimod,
Microcrystalline cellulose,
LCL161,
Hsct,
Imids,
Sti571,
Cc5013
Merck & Co
Interferon alfa-2b,
Ademetionine,
Bomedemstat,
Img-7289
Takeda
Anagrelide
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use